Clinical Guide: Drug-Induced Hypersensitivity Syndrome (DRESS)

1. Comprehensive Introduction & Overview

Drug-Induced Hypersensitivity Syndrome (DRESS), also clinically referred to as Drug Reaction with Eosinophilia and Systemic Symptoms, represents one of the most severe and life-threatening adverse drug reactions in modern medicine. Unlike common drug rashes, DRESS is a multi-system inflammatory condition characterized by a prolonged latency period, extensive cutaneous involvement, hematologic abnormalities, and internal organ dysfunction.

Clinical Definition

DRESS is a type IVb delayed-type hypersensitivity reaction. It is defined by the triad of:
1. Cutaneous eruption: Typically a morbilliform rash progressing to exfoliative dermatitis.
2. Hematologic abnormalities: Primarily eosinophilia, though atypical lymphocytosis is frequently observed.
3. Systemic involvement: Including but not limited to hepatitis, nephritis, pneumonitis, or carditis.

With a mortality rate approaching 10%, early recognition is paramount for the clinician. The hallmark of DRESS is its "delayed" nature; unlike IgE-mediated reactions (anaphylaxis) that occur within minutes to hours, DRESS typically manifests 2 to 8 weeks after the initiation of the offending medication.

2. Deep-Dive: Mechanisms and Pathophysiology

The pathophysiology of DRESS is a complex interplay between genetic predisposition, viral reactivation, and aberrant immune activation.

The Multi-Hit Hypothesis

The current consensus suggests a multi-hit mechanism:
* Genetic Susceptibility: Strong associations exist between specific HLA alleles and DRESS. For example, the HLA-B58:01 allele is strongly associated with Allopurinol-induced DRESS, while HLA-A31:01 is linked to Carbamazepine-induced cases.
* Impaired Drug Metabolism: Patients often exhibit defective detoxification pathways (e.g., epoxide hydrolase deficiency), leading to the accumulation of reactive drug metabolites. These metabolites act as haptens, binding to endogenous proteins and stimulating a robust T-cell response.
* Viral Reactivation: DRESS is unique in its association with the reactivation of Human Herpesviruses, particularly HHV-6, HHV-7, EBV, and CMV. It is hypothesized that the drug-induced immune response triggers an expansion of virus-specific T-cells, which then undergo cross-reactivity with the drug-protein complexes.

Immunological Cascade

1. Antigen Presentation: Drug metabolites are processed by dendritic cells and presented to T-cells.
2. T-cell Expansion: There is a massive expansion of CD4+ and CD8+ T-cells.
3. Cytokine Storm: Elevated levels of IL-5, IL-10, and IFN-gamma are released, driving the recruitment of eosinophils and systemic inflammation.

3. Clinical Indications and Standard Presentation

DRESS is a "great imitator," often mimicking severe infections, connective tissue diseases, or malignancy.

Standard Presentation Table

Diagnostic Criteria: The RegiSCAR Score

Clinicians rely on the RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) scoring system to confirm the diagnosis:

• Final Score: <2 (No DRESS), 2-3 (Possible), 4-5 (Probable), ≥6 (Definite).

4. Risks, Side Effects, and Associated Medications

DRESS can be triggered by a wide array of pharmacologic agents. Identifying the culprit is the most critical step in management.

High-Risk Medications

• Anticonvulsants: Carbamazepine, Phenytoin, Phenobarbital, Lamotrigine.
• Antibiotics: Sulfonamides, Vancomycin, Minocycline, Metronidazole.
• Antigout: Allopurinol (The leading cause in many geriatric populations).
• Antivirals: Abacavir, Nevirapine.

Risks and Complications

• Acute Phase: Acute liver failure, acute tubular necrosis, hemophagocytic lymphohistiocytosis (HLH).
• Long-term: Development of autoimmune diseases (e.g., Type 1 Diabetes, Graves’ disease, or systemic lupus erythematosus) has been documented in the months following resolution, likely due to the massive immune dysregulation that occurred during the acute phase.

5. Differential Diagnosis

Distinguishing DRESS from other conditions is vital, as the treatment pathways differ significantly.

1. SJS/TEN (Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis): Usually shorter latency, rapid skin necrosis/detachment. DRESS has more systemic organ involvement and eosinophilia.
2. Acute Generalized Exanthematous Pustulosis (AGEP): Rapid onset (days), characterized by sterile pustules.
3. Viral Exanthems: Lack the systemic eosinophilia and the characteristic prolonged drug-exposure history.
4. Lymphoma: Persistent lymphadenopathy and hematologic changes can mimic lymphoma; skin biopsy and lymph node biopsy are essential if DRESS is not the primary diagnosis.

6. Management Strategy

1. Immediate Discontinuation: Stop the suspected drug immediately.
2. Supportive Care: Intensive monitoring of fluid/electrolyte balance, nutritional support, and temperature regulation.
3. Pharmacotherapy:
   • Systemic Corticosteroids: The cornerstone of treatment. Prednisone (0.5–1.0 mg/kg/day) is typically initiated and tapered over 6–8 weeks.
   • IVIG: Reserved for cases where corticosteroids are contraindicated or ineffective, particularly when there is significant internal organ failure.
   • Cyclosporine: Emerging as a steroid-sparing agent for refractory cases.

7. Massive FAQ Section

Q1: Can I re-challenge the patient with the offending drug?

A: Absolutely not. Re-challenge can lead to a more severe, potentially fatal recurrence of the syndrome.

Q2: How long should the steroid taper last?

A: A slow taper is mandatory. Rapid withdrawal often results in a "rebound" of symptoms. A minimum of 6 to 8 weeks is standard.

Q3: Why does DRESS take weeks to appear?

A: It is a delayed hypersensitivity reaction requiring time for the drug-protein complexes to be presented, T-cell priming, and the subsequent expansion of these cells.

Q4: Is eosinophilia always present?

A: No. While common, eosinophilia may be absent in up to 30% of patients during the initial presentation.

Q5: What is the risk of autoimmune sequelae?

A: Approximately 10-15% of patients may develop autoimmune disorders within the first year after the DRESS episode.

Q6: Can DRESS be caused by herbal supplements?

A: Yes, there are documented reports of DRESS triggered by herbal medications, highlighting the importance of a thorough medication history.

Q7: Are there specific tests to confirm the culprit drug?

A: Patch testing can be performed 3-6 months after recovery, but it has low sensitivity. Lymphocyte Transformation Tests (LTT) are more sensitive but are not universally available.

Q8: Does the rash always look the same?

A: No. While it often starts as a morbilliform eruption, it can progress to targetoid lesions, vesicles, or generalized erythroderma.

Q9: Is biopsy required for diagnosis?

A: Skin biopsy is recommended to rule out SJS/TEN or lymphoma, but histopathology is often non-specific in DRESS (perivascular lymphocytic infiltrate with eosinophils).

Q10: How do I manage a patient who needs an anticonvulsant after a DRESS episode?

A: You must avoid the structural class of the offending drug. Consultation with a neurologist and an allergist is required to select a safe, non-cross-reacting alternative.

8. Long-Term Prognosis

The prognosis for DRESS is generally favorable if the offending agent is identified and withdrawn early. However, the long-term outlook requires:
* Strict avoidance of the culprit drug and drugs with known cross-reactivity.
* Medical Alert Bracelet: Patients should carry documentation regarding their hypersensitivity.
* Periodic Surveillance: Monitoring of thyroid and metabolic function for up to a year post-resolution to detect late-onset autoimmune complications.

9. Conclusion

DRESS is a clinical diagnosis that mandates a high index of suspicion. The clinician’s role is to act as a detective: identifying the timing of medication introduction, evaluating the systemic organ involvement, and managing the immune response with precision. By following the RegiSCAR criteria and maintaining a conservative steroid taper, clinicians can successfully navigate the complexities of this severe hypersensitivity syndrome.